Last reviewed · How we verify
BCG ampoule vaccine
BCG vaccine works by stimulating a cell-mediated immune response against Mycobacterium tuberculosis.
BCG vaccine works by stimulating a cell-mediated immune response against Mycobacterium tuberculosis. Used for Severe forms of tuberculosis, such as TB meningitis and miliary TB.
At a glance
| Generic name | BCG ampoule vaccine |
|---|---|
| Sponsor | PT Bio Farma |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
BCG vaccine contains a live attenuated strain of Mycobacterium bovis, which is closely related to M. tuberculosis. Upon administration, the vaccine induces an immune response that helps to protect against severe forms of tuberculosis, such as TB meningitis and miliary TB.
Approved indications
- Severe forms of tuberculosis, such as TB meningitis and miliary TB
Common side effects
- Local reaction at injection site
Key clinical trials
- Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS) (PHASE2)
- Safety and Tuberculin Conversion Following BCG Vaccination (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCG ampoule vaccine CI brief — competitive landscape report
- BCG ampoule vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI